Investors at Digital RESI JPM

16 Dec

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

Partnering launches for Digital RESI JPM next week and we are expecting 400-500 investors, including family offices/private wealth, corporate venture capital, large pharma and strategic groups, and more. A diverse assembly of investors participate at every RESI event with a main objective of sourcing early-stage innovations for potential investment, in-licensing, and other partnering strategies. Check out the investors who are currently confirmed to attend:

Confirmed Digital RESI JPM Investors*

*December 16, 2021

CI12162021Don’t miss the last opportunity to save on registration! Early bird rates end tomorrow, so sign up now to save $200! if you are actively fundraising and seeking to engage with investors that could potentially be interested in your technology, do not miss out on this opportunity and secure the best registration price available!

Free Fundraising Bootcamps for Partnering Success at JPM

16 Dec

By Karen Deyo, Director of Investor Research, Israel BD, LSN

Through the years, we at Life Science Nation (LSN) have spoken to startups, investors, service providers and many of the other players in the early-stage life science ecosystem. We have seen what works and what does not, and have put together a series of workshops and bootcamps to pass along this knowledge to emerging startups, to help smooth their journeys and, hopefully, prevent them from making a few common mistakes along the way.

Over the course of the next few weeks, leading up to Digital RESI JPM, January 11-13, LSN staff will be holding a series of free bootcamps for startups. Fundraising executives are welcome to attend as many as they desire! We will cover topics such as (but not limited to): identifying investors who are a fit for you, building a comprehensive marketing collateral package that tells your story, how to optimize your partnering experience at a conference, and how to approach your investor meetings in a way that will increase your chances of a second meeting. Follow the links below to register!



Don’t forget to register for Digital RESI JPM – partnering launches next Monday, December 20, so make sure you are signed up to start booking meetings!

Hot Investor Mandate: Growth Equity Firm Invests Up to $20M in Therapeutics and Medical Device Companies, Starting From Series A Rounds

16 Dec

A venture capital and growth equity firm making investments in life sciences will invest as early as Series A and through growth transactions and is currently investing out of their second fund. The firm looks to invest between $10-20M per investment. The firm is looking for companies with clinical data and/or commercial products. The firm has a preference for funding companies that are repurposing existing approved technologies for new indications. The firm is willing to invest in therapeutics, medical device and diagnostics companies.

The firm has a primary focus on pharmaceuticals / therapeutics, and a secondary focus on medical devices. The firm is agnostic to indication.

The firm plays an active role in their portfolio companies. The firm will take a board seat with any company in which they invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Cross-Border Investment Firm Invests Up to $10M in Therapeutics and Devices With Strong Interest in Technologies with China Market Potential

16 Dec

A venture capital firm founded in 2016 is focused on cross-border investments. When investing, the firm doesn’t only provide financial capital, they also provide their global consulting services focused specifically on helping companies work across borders and in China. Currently, the firm is partnered with the Chinese Government to bring good projects from North America to China and are focused on technologies that are at an advanced stage with patents that are willing to launch in Chinese markets or to set up factories and labs in China. The firm is however, willing to invest smaller amounts in good opportunities that have no interest/fit for the Chinese markets as well. The firm’s major focus within the life sciences is biotech and is focused on seed to series B rounds. The firm generally invests up to $10M USD for Series A deals, is flexible for series B rounds, and invests up to $1M USD for seed stage rounds.

Within the Life Sciences space, the firm is specifically focused on clinical tests, therapeutics, and other biotech technologies. The firm is also interested in medical devices focusing on large disease areas within China such as diabetes and cancer. Additionally, the firm is focused on technologies within these sectors that have a good fit with the Chinese Market or have a strong interest in working in China.

When investing, the firm looks to take a board seat. The firm provides consulting, localization services, and the ability to leverage resources in China to help the company grow alongside their direct equity investment and believe that these abilities can be best leveraged with a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Firm Primarily Invests Up to $10M in USA and Europe, Most Interested in Tech-Based Diagnostics, Life Science Tools, Digital Health Companies

16 Dec

A venture capital firm is looking to invest in tech-based digital health and diagnostics companies looking to expand to the Chinese market. The firm primarily invests in European companies, but will consider companies based in the US as well. The firm looks to leverage their connections to China and the Chinese market on behalf of its portfolio companies. The firm looks to invest between $2-10M in companies, taking a 15-30% equity stake. The firm prefers to be a lead investor, taking an active role in their portfolio companies, and will invest in about 2 companies a year, depending on their fund cycle. In cases where the firm does not invest funds, they are also willing to offer consulting services for equity, connecting companies with strategic partners in China.

The firm has an additional partnership model that, instead of direct investment, licenses technologies through a Chinese platform company, acting as a focused distributor for entry into the Chinese market. This is the firm’s alternate investment approach to bringing these technologies to the Chinese market, by utilizing this Chinese platform company to serve as their portfolio company’s representative in China to navigate the regulatory environment and spearhead all of the sales and marketing.

The firm is interested in tech companies that are not consumer focused. The firm looks for companies such as diagnostics tools or AI/machine learning technologies in the healthcare space. The firm has some experience with pathology diagnostic related companies, but is willing to consider other areas as well. The firm prefers to invest in a few companies within the same area, choosing complementary technologies between their portfolio companies. The firm will consider companies with technologies that are in development or in pilot stages.

The firm is an active investor and takes a board seat for every company in which they invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Western Europe-Based VC Firm Has Interests in All Life Science/Healthcare Related Technologies, With Strongest Interest in Advanced Therapies

16 Dec

A venture capital firm headquartered in Western Europe closed their first fund in 2012 and the portfolio companies have advanced into clinical stages, raised additional funding and one of the companies has recently completed an exit. The firm recently raised a second fund for Pre-Seed, Seed, and Series A investments with a focus in technology transfer in all four life science sectors. The firm invests €1-2M as a seed investment in the form of equity or convertible notes to help companies advance into preclinical proof of concept, and can continue investing up to €6M. If additional funds are needed, the firm seeks co-investments from the strong network of investors they have in Europe. The firm is also looking to expand this network into the US as well. The firm is looking for investments across Europe.

The firm invests in all four life science sectors, but has a particular focus on therapeutics. Within therapeutics the firm has an interest in cutting edge technologies in advanced therapies, gene and cell therapy, gene editing and synthetic biology. The firm is agnostic to subsector and indication and will invest in pre-clinical companies and follow the companies through the development of the project with additional investors. The firm is open to all 3 classes of medical devices.

The firm looks for companies with a scientific founder, and preferably a C Level executive with a track record in biotech or pharmaceutical companies. The firm prefers to lead or co-lead in Seed stage therapeutics companies and will seek a board seat. The firm will co-invest in medtech investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Pitching at Digital RESI JPM

9 Dec

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

It has been more than a year since we’ve introduced the Innovator’s Pitch Challenge (IPC), Life Science Nation’s latest effort to boost exposure for early-stage companies attending the Redefining Early Stage Investment (RESI) conference virtually. Since its inception, the IPC has become one of the most anticipated components of the RESI program. To date, hundreds of early-stage life science and healthcare startups and hundreds of investor and industry expert judges have participated. We are excited to continue growing this dynamic platform of companies and investors, strategic partners, industry experts, and more to facilitate new conversations.

Hear from some of these previous participants about their experience and how the IPC helped them along their fundraising journey:

We are actively accepting applications for the Digital RESI JPM Innovator’s Pitch Challenge, where we will showcase innovative technologies across therapeutics, medical devices, diagnostics/tools, and digital health.

Applications are due Friday, December 17 – it’s not too late to apply!

Apply for IPC with Icon

← Older Entries
Newer Entries →